Crossmark Global Holdings Inc. Purchases 92 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Crossmark Global Holdings Inc. increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,654 shares of the biopharmaceutical company’s stock after acquiring an additional 92 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,890,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of REGN. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $37,000. Truvestments Capital LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $39,000. Finally, Valley Wealth Managers Inc. purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $49,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 2.1 %

REGN stock opened at $694.64 on Friday. The firm has a market cap of $76.33 billion, a PE ratio of 17.19, a P/E/G ratio of 1.62 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm’s fifty day moving average is $730.57 and its 200 day moving average is $942.10. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20.

Analyst Upgrades and Downgrades

Several analysts have weighed in on REGN shares. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Citigroup dropped their target price on shares of Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 14th. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.